Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Naoki Sakurai | M | - |
HISHOH Biopharma Co., Ltd.
 HISHOH Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services HISHOH Biopharma Co., Ltd. is a Japanese company that develops allergen immunotherapy. The company was founded in 2021 by Toru Seo and Naoki Sakurai. Naoki Sakurai has been the CEO since 2021. | 3 years |
| Shin Hatou | M | - |
Cellusion Inc.
 Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Cellusion Inc. is a Japanese company that focuses on regenerating corneal endothelium using IPS cells to treat bullous keratopathy. The company is based in Tokyo, Japan. The company was founded in 2015 by Shigeto Shimmura, Kazuo Tsubota, Shin Hatou. | 9 years |
| Michihito Onishi | M | - |
HISHOH Biopharma Co., Ltd.
HISHOH Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services HISHOH Biopharma Co., Ltd. is a Japanese company that develops allergen immunotherapy. The company was founded in 2021 by Toru Seo and Naoki Sakurai. Naoki Sakurai has been the CEO since 2021. | 3 years |
| Fu Ling Yeh | F | - |
Cellusion Inc.
Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Cellusion Inc. is a Japanese company that focuses on regenerating corneal endothelium using IPS cells to treat bullous keratopathy. The company is based in Tokyo, Japan. The company was founded in 2015 by Shigeto Shimmura, Kazuo Tsubota, Shin Hatou. | - |
| Tomokatsu Hongo | M | - |
Cellusion Inc.
Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Cellusion Inc. is a Japanese company that focuses on regenerating corneal endothelium using IPS cells to treat bullous keratopathy. The company is based in Tokyo, Japan. The company was founded in 2015 by Shigeto Shimmura, Kazuo Tsubota, Shin Hatou. | - |
| Joji Hayashida | M | - |
Cellusion Inc.
Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Cellusion Inc. is a Japanese company that focuses on regenerating corneal endothelium using IPS cells to treat bullous keratopathy. The company is based in Tokyo, Japan. The company was founded in 2015 by Shigeto Shimmura, Kazuo Tsubota, Shin Hatou. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Japan | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Toru Seo
- Personal Network
